Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (291-300 of 308) with videos related to

Pageof 31
Sort By:
NPJ Breast Cancer|January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|February 13, 2025
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancerRita A Mukhtar, Soumya Gottipati, Christina Yau, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
The Lancet. Oncology|December 13, 2021
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patientsChristina Yau, Marie Osdoit, Marieke van der Noordaa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Journal of the National Cancer Institute|April 17, 2018
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois-Clément Bidard, Stefan Michiels, Sabine Riethdorf, et al.
Pageof 31

Showing results (291-300 of 308) with videos related to

Sort By:
Pageof 31
NPJ Breast Cancer|January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|February 13, 2025
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancerRita A Mukhtar, Soumya Gottipati, Christina Yau, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast CancerHope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
The Lancet. Oncology|December 13, 2021
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patientsChristina Yau, Marie Osdoit, Marieke van der Noordaa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Journal of the National Cancer Institute|April 17, 2018
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois-Clément Bidard, Stefan Michiels, Sabine Riethdorf, et al.
Pageof 31